Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2(S)-amino-6-boronohexanoic acid, commonly referred to as ABH, is a synthetic, non-proteinogenic L-alpha-amino acid and an organoboron compound structurally related to L-norleucine. It acts as a highly potent and specific inhibitor of arginase enzymes (arginase I and II). By inhibiting arginase activity, ABH increases the availability of L-arginine for nitric oxide synthase, thereby enhancing nitric oxide production. This mechanism has been shown in preclinical studies to improve endothelial function and erectile hemodynamics in aged rats by reducing elevated arginase activity associated with aging or disease states such as erectile dysfunction. ABH is primarily used experimentally as a biochemical tool for studying the physiological roles of arginases[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2(S)-amino-6-boronohexanoic acid.